000182658 001__ 182658
000182658 005__ 20240229145727.0
000182658 0247_ $$2doi$$a10.3389/fimmu.2022.1029214
000182658 0247_ $$2altmetric$$aaltmetric:138032136
000182658 037__ $$aDKFZ-2022-02830
000182658 082__ $$a610
000182658 1001_ $$aDebelec-Butuner, Bilge$$b0
000182658 245__ $$aActivation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins
000182658 260__ $$aLausanne$$bFrontiers Media$$c2022
000182658 3367_ $$2DRIVER$$aarticle
000182658 3367_ $$2DataCite$$aOutput Types/Journal article
000182658 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1668768795_29164
000182658 3367_ $$2BibTeX$$aARTICLE
000182658 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182658 3367_ $$00$$2EndNote$$aJournal Article
000182658 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000182658 588__ $$aDataset connected to DataCite
000182658 7001_ $$aQuitt, Oliver$$b1
000182658 7001_ $$aSchreiber, Sophia$$b2
000182658 7001_ $$0P:(DE-He78)b2290261145f21c46f2d42783c69d104$$aMomburg, Frank$$b3$$udkfz
000182658 7001_ $$aWisskirchen, Karin$$b4
000182658 7001_ $$aProtzer, Ulrike$$b5
000182658 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2022.1029214$$gVol. 13, p. 1029214$$p1029214$$tFrontiers in immunology$$v13$$x1664-3224$$y2022
000182658 909CO $$ooai:inrepo02.dkfz.de:182658$$pVDB
000182658 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2290261145f21c46f2d42783c69d104$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000182658 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000182658 9141_ $$y2022
000182658 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-29
000182658 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000182658 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000182658 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-29
000182658 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-29
000182658 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2021$$d2022-11-23
000182658 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-23
000182658 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-23
000182658 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T10:28:02Z
000182658 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T10:28:02Z
000182658 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T10:28:02Z
000182658 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-23
000182658 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-23
000182658 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2021$$d2022-11-23
000182658 9201_ $$0I:(DE-He78)D121-20160331$$kD121$$lD121 AG Antigenpräsentation und T/NK-Zell-Aktivierung$$x0
000182658 980__ $$ajournal
000182658 980__ $$aVDB
000182658 980__ $$aI:(DE-He78)D121-20160331
000182658 980__ $$aUNRESTRICTED